keyword
MENU ▼
Read by QxMD icon Read
search

infliximab serum

keyword
https://www.readbyqxmd.com/read/28622097/evolution-of-cytokines-and-inflammatory-biomarkers-during-infliximab-induction-therapy-and-the-impact-of-inflammatory-burden-on-primary-response-in-patients-with-crohn-s-disease
#1
Thomas Billiet, Isabelle Cleynen, Vera Ballet, Karolien Claes, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche, Ann Gils, Severine Vermeire
OBJECTIVE: Primary non-response to infliximab in Crohn's disease is still incompletely understood. Our aim was to further characterize the role of inflammatory burden during infliximab induction therapy. MATERIALS AND METHODS: We studied a well-characterized cohort of 201 anti-TNF naive Crohn's disease patients treated with infliximab 5mg/kg at week 0, 2, 6 and 14 who had serum samples drawn just before every infusion. All serum samples were analyzed for CRP, albumin, TNF, IFN-γ, IL-6, IL-8, IL-10, infliximab trough concentrations (in-house-developed ELISA) and antibodies to infliximab (HMSA, Prometheus Laboratories Inc...
June 16, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28618062/examining-maintenance-care-following-infliximab-salvage-therapy-for-acute-severe-ulcerative-colitis
#2
Dean Seah, Matthew C Choy, Alexandra Gorelik, William R Connell, Miles P Sparrow, Daniel van Langenberg, Geoffrey Hebbard, Gregory Moore, Peter De Cruz
BACKGROUND AND AIMS: Data supporting the optimal maintenance drug therapy & strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance & monitoring strategies employed in patients post IFX induction therapy. METHODS: Patients in 6 Australian tertiary centres treated with IFX for steroid-refractory ASUC between April 2014 & May 2015 were identified via hospital IBD & pharmacy databases...
June 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28565826/transcriptional-profiling-of-leukocytes-from-rheumatoid-arthritis-patients-before-and-after-anti-tumor-necrosis-factor-therapy-a-comparison-of-anti-nuclear-antibody-positive-and-negative-subsets
#3
Laurie S Davis, Andreas M Reimold
Anti-nuclear antibodies (ANAs) may be induced in patients with rheumatoid arthritis (RA) receiving anti-tumor necrosis factor (TNF) therapy with TNF inhibitors (TNFi), etanercept, infliximab or adalimumab. In the present study, 11 patients who were TNFi drug naive were started on TNFi at a time of high disease activity. Of these, all cases were positive for rheumatoid factor and 9 cases tested were positive for anti-citrullinated peptide (anti-CCP) antibodies prior to TNFi treatment. Peripheral blood mononuclear cells (PBMCs) and serum were collected from all patients before and after TNFi therapy...
May 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28514405/-stable-high-interleukin-17a-concentration-in-patients-with-ankylosing-spondylitis-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-during-a-year
#4
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan
AIM: To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. SUBJECTS AND METHODS: Examinations were made in 30 patients (22 (73.3%) men) aged 38.35±9.19 years with AS (modified New-York criteria, BASDAI ≥4.0; AS duration, 11.4±9.6 years) and in 20 healthy individuals (12 (60%) men) aged 40.1±7.7 years) (a control group). All the patients were treated with infliximab (remicade, MSD) 5 mg/kg body weight during a year according to the recommended regimen...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28507492/long-term-treatment-of-chronic-plaque-psoriasis-with-biological-drugs-can-control-platelet-activation-targeting-the-bridge-between-inflammation-and-atherothrombosis
#5
Bartłomiej Kwiek, Joanna Narbutt, Anna Sysa-Jędrzejowska, Andrzej Langner, Aleksandra Lesiak
INTRODUCTION: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation. AIM: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. MATERIAL AND METHODS: An observational study of 27 patients with chronic plaque psoriasis, treated with infliximab, adalimumab, etanercept, or ustekinumab for up to 12 months was conducted...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28481014/infliximab-and-adalimumab-drug-levels-in-crohn-s-disease-contrasting-associations-with-disease-activity-and-influencing-factors
#6
M G Ward, B Warner, N Unsworth, S-W Chuah, C Brownclarke, S Shieh, M Parkes, J D Sanderson, Z Arkir, J Reynolds, P R Gibson, P M Irving
BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn's disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn's disease according to different disease endpoints, and factors that influence drug levels. METHODS: We performed a cross-sectional service evaluation of patients receiving maintenance infliximab or adalimumab for Crohn's disease...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28465139/diagnostic-potential-of-netosis-derived-products-for-disease-activity-atherosclerosis-and-therapeutic-effectiveness-in-rheumatoid-arthritis-patients
#7
C Pérez-Sánchez, P Ruiz-Limón, M A Aguirre, Y Jiménez-Gómez, I Arias-de la Rosa, M C Ábalos-Aguilera, A Rodriguez-Ariza, M C Castro-Villegas, R Ortega-Castro, P Segui, C Martinez, R Gonzalez-Conejero, S Rodríguez-López, J A Gonzalez-Reyes, J M Villalba, E Collantes-Estévez, A Escudero, N Barbarroja, Ch López-Pedrera
OBJECTIVES: 1) To assess the association of NETosis and NETosis-derived products with the activity of the disease and the development of cardiovascular disease in RA; 2) To evaluate the involvement of NETosis on the effects of biologic therapies such as anti-TNF alpha (Infliximab) and anti-IL6R drugs (Tocilizumab). METHODS: One hundred and six RA patients and 40 healthy donors were evaluated for the occurrence of NETosis. Carotid-intimae media thickness was analyzed as early atherosclerosis marker...
April 29, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28459157/infliximab-alleviates-the-mortality-mesenteric-hypoperfusion-aortic-dysfunction-and-multiple-organ-damage-in-septic-rats
#8
Erdem Kamil Ozer, Mustafa Tugrul Goktas, Ibrahim Kilinc, Aysun Toker, Hulagu Bariskaner, Ceyhan Ugurluoglu, Alper Bektas Iskit
Tumor necrosis factor-alpha (TNF-α) is a pivotal mediator that triggers inflammatory process, oxidative stress and multiple organ injury in sepsis. We investigated the effects of infliximab on survival, mesenteric artery blood flow (MBF), vascular reactivity, oxidative and inflammatory injuries in cecal ligation and puncture (CLP) induced sepsis. Wistar rats were divided into Sham, CLP, Sham+infliximab, CLP+infliximab subgroups. 24 hours before the operations rats were injected intraperitoneally with infliximab (7 mg/kg) or vehicle (saline; 1 mL/kg)...
April 29, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28453755/association-of-induction-infliximab-levels-with-clinical-response-in-perianal-crohn-s-disease
#9
Yana Davidov, Bella Ungar, Haggai Bar-Yoseph, Dan Carter, Ola Haj-Natour, Miri Yavzori, Yehuda Chowers, Rami Eliakim, Shomron Ben-Horin, Uri Kopylov
Background: The association of infliximab [IFX] trough levels with clinical and endoscopic outcomes in inflammatory bowel disease is well established. However, there is scarce data regarding the association of perianal fistula response with IFX. The aim of this study was to establish whether early induction infliximab levels and anti-infliximab antibodies [ATIs] are associated with perianal fistula response. Methods: Consecutive CD patients with perianal fistulae that were treated with IFX between 2008 and 2016 were included in the study...
May 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28450388/clinical-relevance-of-detecting-anti-infliximab-antibodies-with-a-drug-tolerant-assay-post-hoc-analysis-of-the-taxit-trial
#10
Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
OBJECTIVE: To evaluate the clinical relevance of antidrug antibodies (ADAs) measured using a drug-tolerant assay in a post hoc analysis of the Trough Concentration (TC) Adapted Infliximab Treatment (TAXIT) randomised controlled trial. DESIGN: ADA in serum samples (n=221) of 76 patients enrolled in TAXIT, who presented with an infliximab TC <3 µg/mL at screening, were reanalysed after optimisation and at the end of the study using a drug-tolerant ADA assay...
April 27, 2017: Gut
https://www.readbyqxmd.com/read/28448562/the-impact-of-anti-drug-antibodies-on-drug-concentrations-and-clinical-outcomes-in-rheumatoid-arthritis-patients-treated-with-adalimumab-etanercept-or-infliximab-results-from-a-multinational-real-world-clinical-practice-non-interventional-study
#11
Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos
OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX...
2017: PloS One
https://www.readbyqxmd.com/read/28425772/prediction-of-successful-dose-reduction-or-discontinuation-of-adalimumab-etanercept-or-infliximab-in-rheumatoid-arthritis-patients-using-serum-drug-levels-and-antidrug-antibody-measurement
#12
RANDOMIZED CONTROLLED TRIAL
Cam Bouman, N van Herwaarden, Fhj van den Hoogen, A van der Maas, Bjf van den Bemt, A A den Broeder
BACKGROUND: To evaluate if TNF inhibitor serum drug levels (DL) or anti-drug antibodies (ADAb) can predict successful dose reduction (in patients with high DL) or discontinuation (in patients with no/low DL or ADAb) in rheumatoid arthritis (RA) patients. RESEARCH DESIGN AND METHODS: RA patients that were using adalimumab (n = 42), etanercept (n = 76) or infliximab (n = 51) and were doing well, were tapered until discontinuation or flare (1-1.5 year follow up)...
June 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28411169/the-impact-of-immunogenicity-of-tnf%C3%AE-inhibitors-in-autoimmune-inflammatory-disease-a-systematic-review-and-meta-analysis
#13
REVIEW
Valentina Pecoraro, Elena De Santis, Alessandra Melegari, Tommaso Trenti
BACKGROUND: Monoclonal antibodies drugs directed against TNFα, TNFα inhibitors, are immunogenic, and consequent anti-drug antibodies (ADA) formation may decrease the functional drug concentration, resulting in a loss of response. We evaluated the impact of ADA on TNFα therapeutic response. METHODS: We considered studies enrolling adult patients affected by autoimmune inflammatory disease in therapy with TNFα inhibitors. We collected data about study and population characteristics, treatment dosage, determination of ADA and adverse events (AE)...
April 12, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28400083/proposal-for-an-anti-tnf-exit-strategy-based-on-trough-serum-level
#14
Ulf Helwig, Frederik Lutter, Nadine Koppka, Stefan Schreiber
BACKGROUND AND AIMS: The aim of the study was to evaluate, if the strategy to stop anti-TNF treatment after determination of low trough serum levels and exclusion of inflammation is associated with lower relapse rates. METHODS: Since 2013 we followed an exit strategy in patients treated with anti-TNF treatment for inflammatory bowel disease based on trough serum levels. The relapse rates were observed prospectively, data analysis was performed in a retrospective manner of the collected clinical data...
April 8, 2017: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/28387583/analytical-ultracentrifugation-with-fluorescence-detection-system-reveals-differences-in-complex-formation-between-recombinant-human-tnf-and-different-biological-tnf-antagonists-in-various-environments
#15
Elena Krayukhina, Masanori Noda, Kentaro Ishii, Takahiro Maruno, Hirotsugu Wakabayashi, Minoru Tada, Takuo Suzuki, Akiko Ishii-Watabe, Masahiko Kato, Susumu Uchiyama
A number of studies have attempted to elucidate the binding mechanism between tumor necrosis factor (TNF) and clinically relevant antagonists. None of these studies, however, have been conducted as close as possible to physiologic conditions, and so the relationship between the size distribution of TNF-antagonist complexes and the antagonists' biological activity or adverse effects remains elusive. Here, we characterized the binding stoichiometry and sizes of soluble TNF-antagonist complexes for adalimumab, infliximab, and etanercept that were formed in human serum and in phosphate-buffered saline (PBS)...
May 2017: MAbs
https://www.readbyqxmd.com/read/28375831/the-effect-of-anti-tnf-treatment-on-osteoblastogenesis-in-ankylosing-spondylitis-the-number-of-circulating-osteoblast-lineage-cells-in-peripheral-blood-decreased-after-infliximab-therapy-in-patients-with-ankylosing-spondylitis
#16
Seong-Ryul Kwon, Kyong-Hee Jung, Mie-Jin Lim, Min-Jung Son, Byung Hyune Choi, Shin-Goo Park, Won Park
OBJECTIVES: The full effect of anti-TNF therapy on new bone formation is still in debate in spondylitis fields. We sought to obtain circulating osteoblast-lineage cells in peripheral blood from ankylosing spondylitis (AS) patients and healthy control subjects, and to evaluate the effect of before and after anti TNF-α therapy on osteoblastogenesis in patients with AS. METHODS: Sixteen male patients with AS slated for infliximab therapy and 19 controls were recruited...
March 31, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28374338/therapeutic-drug-monitoring-of-golimumab-in-the-treatment-of-ulcerative-colitis
#17
REVIEW
Niels Vande Casteele, Reena Khanna
Ulcerative colitis (UC) is a relapsing-remitting chronic inflammatory disorder affecting the mucosal surface in a continuous manner from the rectum through part of, or the entire, colon. Patients with severe disease and those who become refractory or intolerant to corticosteroids and/or immunosuppressants, require treatment with biologic agents that target tumor necrosis factor-α (TNF). Golimumab, a fully human monoclonal antibody, is the latest TNF antagonist to get approved for the treatment of moderate-to-severe UC...
April 3, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28370220/impact-of-anti-tumor-necrosis-factor-%C3%AE-agents-on-serum-levels-of-kl-6-and-surfactant-protein-d-in-patients-with-psoriasis
#18
Mitsuha Hayashi, Koichi Yanaba, Yoshinori Umezawa, Akihiko Asahina, Hidemi Nakagawa
We longitudinally examined the influence of anti-tumor necrosis factor (TNF)-α treatment on serum levels of KL-6 and surfactant protein-D (SP-D). The study group comprised 22 patients with psoriasis treated with infliximab or adalimumab and with no history of interstitial lung disease (ILD). KL-6 and SP-D levels were measured in serum samples. Twelve of the 22 patients (55%) showed at least a 20% increase in KL-6 levels compared with baseline. Of these 12 patients, none exhibited any signs of ILD on chest computed tomography and nine who showed an increase in KL-6 levels (75%) showed at least a 20% increase in SP-D levels...
March 31, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28365486/improved-long-term-outcomes-of-patients-with-inflammatory-bowel-disease-receiving-proactive-compared-with-reactive-monitoring-of-serum-concentrations-of-infliximab
#19
Konstantinos Papamichael, Karen A Chachu, Ravy Vajravelu, Byron P Vaughn, Josephine Ni, Mark T Osterman, Adam S Cheifetz
BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission whose drug has been titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab...
March 30, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28362851/clinical-role-optimal-timing-and-frequency-of-serum-infliximab-and-anti-infliximab-antibody-level-measurements-in-patients-with-inflammatory-bowel-disease
#20
Renáta Bor, Klaudia Farkas, Anna Fábián, Anita Bálint, Ágnes Milassin, Mariann Rutka, Mária Matuz, Ferenc Nagy, Zoltán Szepes, Tamás Molnár
BACKGROUND: Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, that may have a great role in the therapeutic decisions during maintenance biological therapy. RESEARCH DESIGN AND METHODS: 48 inflammatory bowel disease patients receiving maintenance IFX therapy were prospectively enrolled and divided into adequate (complete remission N = 20) and inadequate responder (partial response, loss of response, dose escalation; N = 28) groups...
2017: PloS One
keyword
keyword
43807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"